Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases

Acta Neuropathologica

Volumn 123, Issue 2, 2012, Pages 223-233

  Capper, David ^a,b   Berghoff, Anna Sophie ^c   Magerle, Manuel ^c   Ilhan, Aysegül ^c   Wöhrer, Adelheid ^c,d   Hackl, Monika ^e   Pichler, Josef ^f   Pusch, Stefan ^a,b   Meyer, Jochen ^a,b   Habel, Antje ^a   Petzelbauer, Peter ^g   Birner, Peter ^c   Von Deimling, Andreas ^a,b   Preusser, Matthias ^a,c,d  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e Austrian National Cancer Registry   (Austria)

^f KEPLER UNIVERSITY HOSPITAL   (Austria)

^g Universitatsklinik fur Dermatologie   (Austria)

Author keywords

BRAF V600E; Brain metastases; Immunohistochemistry; Mutation; VE1

Indexed keywords

B RAF KINASE;

ADOLESCENT; AGED; ARTICLE; BRAIN METASTASIS; CANCER SURGERY; CELL AGGREGATION; CHORIOCARCINOMA; CLINICAL FEATURE; COLORECTAL CANCER; CONTROLLED STUDY; EMBRYO; EXON; FEMALE; GENE EXPRESSION PROFILING; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CANCER; MALE; MELANOMA; MOLECULAR IMAGING; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; ONSET AGE; OVARY CANCER; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; THYROID CANCER; WESTERN BLOTTING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GLUTAMIC ACID; HEK293 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; POINT MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; VALINE; YOUNG ADULT;

EID: 84857030136     PISSN: 00016322     EISSN: 14320533     Source Type: Journal    
DOI: 10.1007/s00401-011-0887-y     Document Type: Article

References (28)

1. M Arcila C Lau K Nafa M Ladanyi 2011 Detection of KRAS and BRAF mutations in colorectal carcinoma roles for high-sensitivity locked nucleic acid-PCR sequencing and broad-spectrum mass spectrometry genotyping J Mol Diagn 13 64 73 21227396 10.1016/j.jmoldx.2010.11.005 1:CAS:528:DC%2BC3MXisVCisbw%3D
2. D Capper M Preusser A Habel, et al. 2011 Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody Acta Neuropathol 122 11 19 21638088 10.1007/s00401-011-0841-z 1:CAS:528:DC%2BC3MXnvVKnsr0%3D
3. D Capper S Weissert J Balss, et al. 2010 Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors Brain Pathol 20 245 254 19903171 10.1111/j.1750-3639.2009.00352.x 1:CAS:528:DC%2BC3cXpvFOlsA%3D%3D
4. D Capper H Zentgraf J Balss C Hartmann A von Deimling 2009 Monoclonal antibody specific for IDH1 R132H mutation Acta Neuropathol 118 599 601 19798509 10.1007/s00401-009-0595-z 1:CAS:528:DC%2BD1MXhtlKitLrK
5. PB Chapman A Hauschild C Robert, et al. 2011 Improved survival with vemurafenib in melanoma with BRAF V600E mutation N Engl J Med 364 2507 2516 21639808 10.1056/NEJMoa1103782 1:CAS:528:DC%2BC3MXosVeitbs%3D
6. E Edlundh-Rose S Egyhazi K Omholt, et al. 2006 NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing Melanoma Res 16 471 478 17119447 10.1097/01.cmr.0000232300.22032.86 1:CAS:528:DC%2BD28Xht1antrvL (Pubitemid 44934704)
7. KT Flaherty I Puzanov KB Kim, et al. 2010 Inhibition of mutated, activated BRAF in metastatic melanoma N Engl J Med 363 809 819 20818844 10.1056/NEJMoa1002011 1:CAS:528:DC%2BC3cXhtVyksb3M
8. Forbes SA, Bhamra G, Bamford S et al (2008) The catalogue of somatic mutations in cancer (COSMIC). Curr Protoc Hum Genet Chapter 10:Unit 10 11
9. FG Kamar JB Posner 2010 Brain metastases Semin Neurol 30 217 235 20577929 10.1055/s-0030-1255225
10. Y Kienast F Winkler 2010 Therapy and prophylaxis of brain metastases Expert Rev Anticancer Ther 10 1763 1777 21080803 10.1586/era.10.165
11. ET Kimura MN Nikiforova Z Zhu JA Knauf YE Nikiforov JA Fagin 2003 High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma Cancer Res 63 1454 1457 12670889 1:CAS:528: DC%2BD3sXisFaisLs%3D (Pubitemid 36373628)
12. HV Küsters-Vandevelde A Klaasen B Kusters, et al. 2010 Activating mutations of the GNAQ gene: a frequent event in primary melanocytic neoplasms of the central nervous system Acta Neuropathol 119 317 323 19936769 10.1007/s00401-009-0611-3
13. Long GV, Kefford RF, Carr PJA et al (2010) Phase 1/2 study of GSK2118436, a selective inhibitor of V600 mutant BRAF kinase: evidence of activity in melanoma brain metastases. Ann Oncol LBA27
14. GV Long AM Menzies AM Nagrial, et al. 2011 Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma J Clin Oncol 29 1239 1246 21343559 10.1200/JCO.2010.32.4327
15. S Magnin E Viel A Baraquin, et al. 2011 A multiplex SNaPshot assay as a rapid method for detecting KRAS and BRAF mutations in advanced colorectal cancers J Mol Diagn 13 485 492 21742054 10.1016/j.jmoldx.2011.05.010 1:CAS:528:DC%2BC3MXht1Clt77M
16. PK Paik ME Arcila M Fara, et al. 2011 Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations J Clin Oncol 29 2046 2051 21483012 10.1200/JCO.2010.33.1280
17. Papadatos-Pastos D, Banerji U (2011) Revisiting the role of molecular targeted therapies in patients with brain metastases. J Neurooncol ISSN: 1573-7373
18. A Platz S Egyhazi U Ringborg J Hansson 2008 Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site Mol Oncol 1 395 405 19383313 10.1016/j.molonc.2007.12.003
19. Preusser M, Capper D, Hartmann C (2011) IDH testing in diagnostic neuropathology: review and practical guideline article invited by the Euro-CNS research committee. Clin Neuropathol (in press)
20. M Preusser A Wohrer S Stary R Hoftberger B Streubel JA Hainfellner 2011 Value and limitations of immunohistochemistry and gene sequencing for detection of the IDH1-R132H mutation in diffuse glioma biopsy specimens J Neuropathol Exp Neurol 70 715 723 21760534 10.1097/NEN.0b013e31822713f0 1:CAS:528: DC%2BC3MXptVeqtrw%3D
21. G Schindler D Capper J Meyer, et al. 2011 Analysis of BRAF V600E mutation in 1, 320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma Acta Neuropathol 121 397 405 21274720 10.1007/s00401-011-0802-6 1:CAS:528:DC%2BC3MXhvVyrsrk%3D
22. G Singer R Oldt 3rd Y Cohen, et al. 2003 Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma J Natl Cancer Inst 95 484 486 12644542 10.1093/jnci/95.6.484 1:CAS:528:DC%2BD3sXisFCqs70%3D (Pubitemid 36432423)
23. A Tannapfel F Sommerer M Benicke, et al. 2003 Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma Gut 52 706 712 12692057 10.1136/gut.52.5.706 1:CAS:528:DC%2BD3sXjvVeiu7g%3D (Pubitemid 36528874)
24. E Tiacci V Trifonov G Schiavoni, et al. 2011 BRAF mutations in hairy-cell leukemia N Engl J Med 364 2305 2315 21663470 10.1056/NEJMoa1014209 1:CAS:528:DC%2BC3MXns12it78%3D
25. A Vultur J Villanueva M Herlyn 2011 Targeting BRAF in advanced melanoma: a first step toward manageable disease Clin Cancer Res 17 1658 1663 21447722 10.1158/1078-0432.CCR-10-0174 1:CAS:528:DC%2BC3MXktVOisrw%3D
26. PT Wan MJ Garnett SM Roe, et al. 2004 Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF Cell 116 855 867 15035987 10.1016/S0092-8674(04)00215-6 1:CAS:528:DC%2BD2cXivVyksLw%3D (Pubitemid 38410730)
27. A Wohrer T Waldhor H Heinzl, et al. 2009 The Austrian brain tumour registry: a cooperative way to establish a population-based brain tumour registry J Neurooncol 95 401 411 19562257 10.1007/s11060-009-9938-9
28. ST Yuen H Davies TL Chan, et al. 2002 Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia Cancer Res 62 6451 6455 12438234 1:CAS:528:DC%2BD38XovFOlu70%3D (Pubitemid 35364105)